ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2015
Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity.Angiogenesis · 2024Article
- Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity.Research square · 2024Article
- Saudi Arabia Guidelines for diabetic macular edema: A consensus of the Saudi Retina Group.Saudi medical journal · 2021Article
- Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience.Frontiers in medicine · 2021Article
- Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion.BMC ophthalmology · 2020Article
- Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF TherapyTurkish journal of ophthalmology · 2019Article
- Dexamethasone implant in the management of diabetic macular edema from clinician's perspective.Clinical ophthalmology (Auckland, N.Z.) · 2019Review
- Systemic Effects of Repeated Intraocular Dexamethasone Intravitreal Implant in Diabetic Patients: A Retrospective Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- New Drugs and New Posterior Delivery Methods in CME.Current ophthalmology reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic macular edema (DME) is the leading cause of sight-threatening complication in diabetic patients, and several treatment modalities have been developed and evaluated to treat this pathology. Intravitreal agents, such as anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids, have become more popular in recent years and are widely used for treating DME. Sustained release drugs appear to be mentioned more often nowadays for extending the period of intravitreal activity, and corticosteroids play a key role in inhibiting the inflammatory process in DME. A potent corticosteroid, dexamethasone (Ozurdex(®)), in the form of an intravitreal implant, has been approved for various ocular etiologies among which DME is also one. This review evaluates the role of implants in the treatment of DME, mainly focusing on the dexamethasone intravitreal implant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.